Counterfeit Drugs Produced In China Still Threaten Chinese, U.S., Global Consumers
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Unless China does more to crack down on counterfeiting and contamination in its pharmaceutical industry, the United States could see a repeat of Chinese-made drugs or raw components causing severe adverse reactions in American hospitals, according to a Washington, D.C.-based scholar
You may also be interested in...
China Broadens Scope Of Counterfeit Drugs For Criminal Prosecution, But Definition Still Murky
SHANGHAI - China recently broadened its criminal definition of counterfeit drugs to include all counterfeits, not just those that cause damage to human health. The revised Criminal Law opens more manufacturers of counterfeit drugs to criminal prosecution and makes prison terms mandatory for guilty parties
China Broadens Scope Of Counterfeit Drugs For Criminal Prosecution, But Definition Still Murky
SHANGHAI - China recently broadened its criminal definition of counterfeit drugs to include all counterfeits, not just those that cause damage to human health. The revised Criminal Law opens more manufacturers of counterfeit drugs to criminal prosecution and makes prison terms mandatory for guilty parties
China's Delays In Approving Clinical Trials, Poor IPR Block Access To Innovative Drugs - EU Chamber Of Commerce
BEIJING - China's lengthy process in reviewing clinical trial applications, unpredictable schedule for updating the national catalog of reimbursable drugs, and lax protection of intellectual property rights are all blocking access for most Chinese citizens to the latest innovative medicines developed worldwide, according to a leader in the European Union Chamber of Commerce in China